BC Week In Review | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in...
BC Week In Review | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

Preliminary data from 3 patients with moderate to extensive bullous pemphigoid in an open-label, U.S. and Israeli Phase II trial showed that 10 mg/kg IV bertilimumab on days 0, 14 and 28 led to a...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

Alkahest Inc. is identifying factors in human plasma that could serve as therapeutics or novel targets used to treat age-related conditions, including Alzheimer's disease. The newco's work stems from the lab of co-founder Tony Wyss-Coray,...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
BC Week In Review | Feb 8, 2016
Company News

iCo ophthalmic, autoimmune, infectious news

iCo terminated all employees to preserve cash. In 2014, iCo reported that iCo-007 failed in a Phase II trial to treat diabetic macular edema (DME). The company said it has since conducted “an exhaustive search...
BC Week In Review | Jul 20, 2015
Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began an open-label, Israeli Phase II trial to evaluate 2 doses of IV bertilimumab given 14 days apart in 10 patients with moderate to severe bullous pemphigoid. Patients will also receive oral prednisone....
BC Week In Review | Sep 29, 2014
Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began a double blind, placebo-controlled, Israeli Phase II trial to evaluate 3 doses of 10 mg/kg IV bertilimumab given 2 weeks apart in about 42 adults with UC. Immune Pharmaceuticals has rights to...
BC Week In Review | Aug 18, 2014
Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began patient screening in an open-label Phase II trial to evaluate 2 doses of 10 mg/kg IV bertilimumab given 14 days apart in 10-15 patients with moderate to severe bullous pemphigoid. Patients will...
BC Week In Review | Mar 4, 2013
Clinical News

Bertilimumab: Phase II start

In April, Immune Pharmaceuticals will begin a double-blind, placebo-controlled, international Phase II trial to evaluate 7 mg/kg IV bertilimumab every other week for 4 weeks in about 90 patients with active moderate to severe UC....
BC Week In Review | Nov 12, 2012
Company News

EpiCept, Immune Pharmaceuticals deal

The companies announced they will merge in a stock deal. After the deal, which is expected to close next quarter, former EpiCept shareholders will own 22.5% of the combined company, which will be named Immune...
Items per page:
1 - 10 of 23